Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003948 Phase 1 in Healthy Participants
NCT06832657Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in age-related macular degeneration (AMD) and diabetic macular edema (DME) comparing JMKX003948 with Placebo (2 arms). Primary endpoints: Adverse events (AEs) and Number of Participants With abnormal Ophthalmic examination. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
JMKX003948
03
Conditions
age-related macular degeneration (AMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06832657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832657.